Hezhao Ji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5005921/publications.pdf

Version: 2024-02-01

32	954	14	30
papers	citations	h-index	g-index
33	33 docs citations	33	1085
all docs		times ranked	citing authors

#	Article	IF	CITATIONS
1	Identification of a Chlamydial Protease–Like Activity Factor Responsible for the Degradation of Host Transcription Factors. Journal of Experimental Medicine, 2001, 193, 935-942.	8.5	363
2	Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Lancet HIV,the, 2016, 3, e579-e591.	4.7	79
3	Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. Molecular and Cellular Biochemistry, 2000, 215, 123-128.	3.1	55
4	Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. Scientific Reports, 2020, 10, 1634.	3.3	45
5	Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. Viruses, 2020, 12, 617.	3.3	40
6	Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology, 2015, 477, 1-9.	2.4	36
7	A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance. Scientific Reports, 2019, 9, 8970.	3.3	36
8	Bioinformatic data processing pipelines in support of nextâ€generation sequencingâ€based <scp>HIV</scp> drug resistance testing: the Winnipeg Consensus. Journal of the International AIDS Society, 2018, 21, e25193.	3.0	34
9	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. Viruses, 2020, 12, 694.	3.3	34
10	Next-Generation Sequencing of Dried Blood Spot Specimens: A Novel Approach to HIV Drug-Resistance Surveillance. Antiviral Therapy, 2011, 16, 871-878.	1.0	31
11	HIV Drug Resistance Surveillance Using Pooled Pyrosequencing. PLoS ONE, 2010, 5, e9263.	2.5	29
12	Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus―Symposium. Viruses, 2020, 12, 586.	3.3	18
13	Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, e1-e3.	2.1	17
14	Novel interferon regulatory factor-1 polymorphisms in a Kenyan population revealed by complete gene sequencing. Journal of Human Genetics, 2004, 49, 528-535.	2.3	14
15	Reduced HIV-1 long terminal repeat transcription in subjects with protective interferon regulatory factor-1 genotype: A potential mechanism mediating resistance to infection by HIV-1. Scandinavian Journal of Infectious Diseases, 2010, 42, 389-394.	1.5	14
16	External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges. Viruses, 2020, 12, 550.	3.3	13
17	Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites. PLoS ONE, 2016, 11, e0157340.	2.5	13
18	Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing. Journal of Virological Methods, 2013, 187, 314-320.	2.1	12

#	Article	IF	CITATIONS
19	Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Na $ ilde{A}^-$ ve and Experienced Patients. PLoS ONE, 2013, 8, e56170.	2.5	12
20	A Robust PCR Protocol for HIV Drug Resistance Testing on Low-Level Viremia Samples. BioMed Research International, 2017, 2017, 1-6.	1.9	10
21	Development and Application of Performance Assessment Criteria for Next-Generation Sequencing-Based HIV Drug Resistance Assays. Viruses, 2020, 12, 627.	3.3	10
22	External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations. Viruses, 2020, 12, 556.	3.3	7
23	Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing. Viruses, 2020, 12, 666.	3.3	6
24	Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials. Pathogens, 2022, 11, 724.	2.8	6
25	Rectal microbiota diversity in Kenyan MSM is inversely associated with frequency of receptive anal sex, independent of HIV status. Aids, 2021, 35, 1091-1101.	2.2	5
26	Probe Capture Enrichment Methods for HIV and HCV Genome Sequencing and Drug Resistance Genotyping. Pathogens, 2022, 11, 693.	2.8	3
27	Human interferon regulatory factor-1 gene and its promoter sequences revealed by population-based complete gene sequencing. DNA Sequence, 2008, 19, 326-331.	0.7	2
28	Application of a Sanger-Based External Quality Assurance Strategy for the Transition of HIV-1 Drug Resistance Assays to Next Generation Sequencing. Viruses, 2020, 12, 1456.	3.3	2
29	Assessment of the Hepatitis C Surveillance System in Henan, China: 2014~2016. BioMed Research International, 2018, 2018, 1-8.	1.9	1
30	PCR Amplification Strategies Towards Full-length HIV-1 Genome Sequencing. Current HIV Research, 2018, 16, 98-105.	0.5	1
31	Overview of the Analytes Applied in Genotypic HIV Drug Resistance Testing. Pathogens, 2022, 11, 739.	2.8	1
32	CAVES: A Novel Tool for Comparative Analysis of Variant Epitope Sequences. Viruses, 2022, 14, 1152.	3.3	0